Literature DB >> 1369684

Neurite growth-promoting protein (amphoterin, p30) binds syndecan.

M Salmivirta1, H Rauvala, K Elenius, M Jalkanen.   

Abstract

A new ligand for syndecan (a cell surface heparan sulfate-rich proteoglycan) has been discovered. In the solid-phase binding assay utilizing small nitrocellulose discs to immobilize matrix molecules, binding of syndecan to neurite growth-promoting protein, p30/amphoterin, was observed. This binding was strongly dependent on the concentration of amphoterin used to coat the discs, but was saturable with an excess amount of syndecan. The interaction was inhibitable with heparan sulfate and heparin but less effectively with chondroitin sulfate, indicating that heparan sulfate chains of syndecan were involved in the binding. Anti-amphoterin antibodies inhibited the binding partially. Mouse mammary epithelial cells were shown to bind amphoterin directly but not after trypsin treatment or in the presence of heparin and to produce amphoterin in the extracellular space. Both syndecan and amphoterin were found to localize on lateral surfaces of newly adhered mammary epithelial cells. Toward confluency amphoterin amounts decreased. Because amphoterin can be localized to the same sites with syndecan and because of their interaction, amphoterin is a new putative pericellular ligand for syndecan. These interactions may be involved in the regulation of cell behavior.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1369684     DOI: 10.1016/0014-4827(92)90194-d

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  26 in total

Review 1.  New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal.

Authors:  S Müller; P Scaffidi; B Degryse; T Bonaldi; L Ronfani; A Agresti; M Beltrame; M E Bianchi
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

Review 2.  Post-translational modifications of high mobility group box 1 and cancer.

Authors:  Seidu A Richard; Yuanyuan Jiang; Lu Hong Xiang; Shanshan Zhou; Jia Wang; Zhaoliang Su; Huaxi Xu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 3.  Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting.

Authors:  Georgina S Butler; Christopher M Overall
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

4.  Activity of the HMGB1-derived immunostimulatory peptide Hp91 resides in the helical C-terminal portion and is enhanced by dimerization.

Authors:  R Saenz; B Messmer; D Futalan; Y Tor; M Larsson; G Daniels; S Esener; D Messmer
Journal:  Mol Immunol       Date:  2013-10-26       Impact factor: 4.407

Review 5.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

6.  Tanshinone IIA sodium sulfonate facilitates endocytic HMGB1 uptake.

Authors:  Yusong Zhang; Wei Li; Shu Zhu; Arvin Jundoria; Jianhua Li; Huan Yang; Saijun Fan; Ping Wang; Kevin J Tracey; Andrew E Sama; Haichao Wang
Journal:  Biochem Pharmacol       Date:  2012-09-26       Impact factor: 5.858

7.  Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule.

Authors:  Claudia Schlueter; Holger Weber; Britta Meyer; Piere Rogalla; Kerstin Röser; Sven Hauke; Jörn Bullerdiek
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 8.  Syndecan family of cell surface proteoglycans: developmentally regulated receptors for extracellular effector molecules.

Authors:  M Salmivirta; M Jalkanen
Journal:  Experientia       Date:  1995-09-29

9.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

Review 10.  Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review.

Authors:  Ben Lu; Ce Wang; Mao Wang; Wei Li; Fangping Chen; Kevin J Tracey; Haichao Wang
Journal:  Expert Rev Clin Immunol       Date:  2014-04-19       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.